Risk factors for non-cure among new sputum smear positive tuberculosis patients treated in tuberculosis dispensaries in Yunnan, China

BMC Health Services Research

Volumn 11, Issue , 2011, Pages

  Jianzhao, Hua ^a   Van Den Hof, Susan ^b,c   Lin, Xu ^a   Yubang, Qiu ^a   Jinglong, Hou ^a   Van Der Werf, Marieke J ^b,c  

^a YUNNAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CHEMISTRY; CHINA; COMMUNITY CARE; DIRECTLY OBSERVED THERAPY; ECONOMICS; FEMALE; HUMAN; ISOLATION AND PURIFICATION; LUNG TUBERCULOSIS; MALE; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATIENT EDUCATION; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SPUTUM; STATISTICAL MODEL; STATISTICS; TREATMENT FAILURE;

ADULT; ANTITUBERCULAR AGENTS; CHINA; COMMUNITY HEALTH SERVICES; DIRECTLY OBSERVED THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MYCOBACTERIUM TUBERCULOSIS; PATIENT EDUCATION AS TOPIC; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SPUTUM; STATISTICS AS TOPIC; TREATMENT FAILURE; TUBERCULOSIS, PULMONARY;

EID: 79958817865     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-11-97     Document Type: Article

References (31)

1. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. C Dye GP Gamett K Sleeman BG Williams, Lancet 1998 352 1886 91 10.1016/S0140-6736(98)03199-7 9863786 (Pubitemid 28561249)
2. Treatment of Tuberculosis Guidelines for National Program. World Health Organization, WHO/CDS/TB/2003.313 Geneva, Switzerland: World Health Organization Third 2003
3. Non-adherence in tuberculosis treatment: predictors and consequences in New York City. A Pablos-Méndez CA Knirsch RG Barr BH Lerner TR Frieden, Am J Med 1997 102 164 170 10.1016/S0002-9343(96)00402-0 9217566 (Pubitemid 27122998)
4. Directly observed therapy (DOT) is not the entire answer: an operational cohort analysis. B Mangura E Napolitano M Passannante M Sarrel R McDonald K Galanowsky L Reichman, Int J Tuberc Lung Dis 2002 6 654 661 12150475 (Pubitemid 34832143)
5. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS program in Tiruvallur District, South India, 2000. T Santha R Garg TR Frieden V Chandrasekaran R Subramani PG Gopi N Selvakumar S Ganapathy N Charles J Rajamma PR Narayanan, Int J Tuberc Lung Dis 2002 6 780 788 12234133 (Pubitemid 34988048)
6. Non-adherence to tuberculosis treatment in eastern Tarai of Nepal. DF Wares S Singh AK Acharya R Dangi, Int J Tuberc Lung Dis 2003 7 327 335 12729337 (Pubitemid 36433124)
7. Predictors of treatment failure among tuberculosis patients under DOTS strategy in Egypt. AM Morsy HH Zaher MH Hassan A Shouman, East Mediterr Health J 2003 9 689 701 15748066 (Pubitemid 40485307)
8. Analysis of multiple factors of outcome in tuberculosis patients under chemotherapy. D Hu HZ Tan J Quan, China Tropical Medicine 2004 4 712 713
9. Tuberculosis treatment adherence and fatality in Spain. JA Cayl T Rodrigo J Ruiz-Manzano JA Caminero R Vidal JM García R Blanquer M Casals Working Group on Completion of Tuberculosis Treatment in Spain (Study ECUTTE), Respiratory Research 2009 10 121 10.1186/1465-9921-10-121 19951437
10. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. W Xu W Lu Y Zhou H Shen J Wang, BMC Health Serv Res 2009 9 169 10.1186/1472-6963-9-169 19765290
11. Factors that influence treatment adherence of tuberculosis patients living in Java, Indonesia. B Widjanarko M Gompelman M Dijkers MJ van der Werf, Patient Prefer Adherence 2009 3 231 238 19936166
12. What lessons can de drawn from tuberculosis Control in China in the 1990s? An analysis from a health system perspective. S Tang SB Squire, Health Policy 2005 72 93 104 10.1016/j.healthpol.2004.06.009 15760702 (Pubitemid 40349011)
13. Centers for Disease Control and Prevention, National Center for Tuberculosis Control, Beijing, China. National TB Control Program in 2005 work plan, 2005
14. Laboratory services in tuberculosis control. World Health Organization, Part II: microscopy. WHO/TB/98.258 Geneva, Switzerland: World Health Organization 1998
15. Risk factors for poor tuberculosis treatment outcome in Finland: a cohort study. T Vasankari P Holmström J Ollgren,, et al. BMC Public Health 2007 7 291 10.1186/1471-2458-7-291 17935630
16. Treatment outcome of new pulmonary tuberculosis in Guangzhou, China. QS Bao YH Du CY Lu, BMC Public Health 2007 7 344 10.1186/1471-2458-7-344 18047661
17. Noncompliance With Directly Observed Therapy for Tuberculosis: Epidemiology and Effect on the Outcome of Treatment. WJ Burman DL Cohn CA Rietmeijer FN Judson JA Sbarbaro RR Reves, Chest 1997 111 1168 1173 10.1378/chest.111.5.1168 9149565 (Pubitemid 27200067)
18. Drug-resistant tuberculosis in South African gold miners: incidence and associated factors. GJ Churchyard EL Corbett I Kleinschmidt D Mulder KM De Cock, Int J Tuberc Lung Dis 2000 4 433 440 10815737 (Pubitemid 30256846)
19. DOT or not? Direct observation of anti-tuberculosis treatment and patient outcomes, Kerala State, India. VN Balasubramanian K Oommen R Samuel, Int J Tuberc lung Dis 2000 4 409 413 10815733 (Pubitemid 30256842)
20. Treatment outcome of Singapore residents with pulmonary tuberculosis in the first year after introduction of a computerized treatment surveillance module. CB Chee YT Wang MD Teleman IC Boudville SK Chew, Singapore Med J 2006 47 529 533 16752023 (Pubitemid 43900501)
21. The Directly Observed Therapy Short-Course (DOTS) strategy in Samara oblast, Russian Federation. Y Balabanova F Drobniewski I Fedorin S Zakharova V Nikolayevskyy R Atun R Coker, Respir Research 2006 7 44 10.1186/1465-9921-7-44
22. Community vs. facility-based directly observed treatment for tuberculosis in Tanzania's Kilimanjaro Region. J van den Boogaard R Lyimo CF Irongo MJ Boeree H Schaalma RE Aarnoutse GS Kibiki, Int J Tuberc Lung Dis 2009 13 1524 1529 19919771
23. DOT in rural China: experience from a case study in Shandong Province, China. Q Sun Q Meng W Yip X Yin H Li, Int J Tuberc Lung Dis 2008 12 625 630 18492328 (Pubitemid 351846759)
24. Risk factors for death during tuberculosis treatment in Orel, Russia. PK Dewan PM Arguin H Kiryanova NV Kondroshova TM Khorosheva K Laserson H Kluge W Jakubowiak C Wells B Kazionny, Int J Tuberc Lung Dis 2004 8 598 602 15137537 (Pubitemid 38625066)
25. Treatment outcome of new culture positive pulmonary tuberculosis in Norway. MG Farah A Tverdal TW Steen E Heldal AB Brantsaeter G Bjune, BMC Public Health 2005 5 14 10.1186/1471-2458-5-14 15698472
26. Association of conversion & cure with initial smear grading among new smear positive pulmonary tuberculosis patients treated with Category I regimen. PG Gopi V Chandrasekaran R Subramani T Santha A Thomas N Selvakumar PR Narayanan, Indian J med Res 2006 123 807 814 16885603 (Pubitemid 44269948)
27. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. WM Jakubowiak EM Bogorodskaya SE Borisov ID Danilova EV Kourbatova, Int J Tuberc Lung Dis 2007 11 46 53 17217129 (Pubitemid 46101845)
28. Public awareness of tuberculosis in China: a national survey of 69253 subjects. SH Lu BC Tian XP Kang W Zhang XP Meng JB Zhang SK Lo, Int J Tuberc Lung Dis 2009 13 1493 1499 19919766
29. Tuberculosis patient expenditure on drugs and tests in subsidised, public services in China: a descriptive study. Q Liu H Smith Y Wang S Tang Q Wang P Garner, Tropical Medicine and International Health 2010 15 26 32 19917035
30. Direct observation and adherence to tuberculosis treatment in Chongqing, China: a descriptive study. D Hu X Liu J Chen Y Wang T Wang W Zeng H Smith P Garner, Health Policy and Planning 2008 23 43 55 18156634
31. How affordable are tuberculosis diagnosis and treatment in rural China? An analysis from community and tuberculosis patient perspectives. X Liu R Thomson Y Gong F Zhao SB Squire R Tolhurst X Zhao F Yan S Tang, Tropical Medicine and International Health 2007 12 1464 1471 10.1111/j.1365-3156.2007. 01953.x 18076553 (Pubitemid 350212712)